225 Actinium-FPI-1434

N/A

Report date: 2025/09/12 15:57:55

Base Information

Drug Name225 Actinium-FPI-1434
Drug Alias Name225Ac-FPI-1434[225Ac]-FPI-1434FPX-01FPI-1434
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225Ac +[4] 
Mechanisms of ActionAnti-Insulin-like growth factor I receptorIonising radiation emitters
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsUveal melanomaSolid tumoursUterine Cervical Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCentre For Probe Development And Commercialization
China Registration ClassN/A

Develop Information

Active CompaniesFusion Pharma
Inactive CompaniesFusion Pharmaceuticals Inc
Active IndicationsNeoplasms
Inactive IndicationsUveal melanomaSolid tumoursUterine Cervical Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksN/A